Abstract:Abstract Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in South African men and women; HVTN 705 in sub-Saharan African women; HVTN 703/HPTN 081 in sub-Saharan African women; HVTN 704/HPTN 085 in U.S., Peruvian, Brazilian, and Swiss men or transgender persons who have sex with men). Several challenges are posed to the optimal design of the sequel efficacy trials, including: (1) how to account for the evolving mosaic of effective prevention interventions that may be part of the trial design or standard of prevention; (2) how to define viable and optimal sequel trial designs depending on the primary efficacy results and secondary “correlates of protection” results of each of the ongoing trials; and (3) how to define the primary objective of sequel efficacy trials if HIV-1 incidence is expected to be very low in all study arms such that a standard trial design has a steep opportunity cost. After summarizing the ongoing trials, I discuss statistical science considerations for sequel efficacy trial designs, both generally and specifically to each trial listed above. One conclusion is that the results of “correlates of protection” analyses, which ascertain how different host immunological markers and HIV-1 viral features impact HIV-1 risk and prevention efficacy, have an important influence on sequel trial design. This influence is especially relevant for the monoclonal antibody trials because of the focused pre-trial hypothesis that potency and coverage of serum neutralization constitutes a surrogate endpoint for HIV-1 infection. Another conclusion is that while assessing prevention efficacy against a counterfactual placebo group is fraught with risks for bias, such analysis is nonetheless important and study designs coupled with analysis methods should be developed to optimize such inferences. I draw a parallel with non-inferiority designs, which are fraught with risks given the necessity of making unverifiable assumptions for interpreting results, but nevertheless have been accepted when a superiority design is not possible and a rigorous/conservative non-inferiority margin is used. In a similar way, counterfactual placebo group efficacy analysis should use rigorous/conservative inference techniques that formally build in a rigorous/conservative margin to potential biases that could occur due to departures from unverifiable assumptions. Because reliability of this approach would require new techniques for verifying that the study cohort experienced substantial exposure to HIV-1, currently it may be appropriate as a secondary objective but not as a primary objective.

Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs

Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials

Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs

Post-randomization Biomarker Effect Modification in an HIV Vaccine Clinical Trial

Accelerate Vaccine Development Using Seamless Phase 2/3 Trial Designs

Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial

Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions

Quantifying Efficiency Gains of Innovative Designs of Two-Arm Vaccine Trials for COVID-19 Using an Epidemic Simulation Model

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study

Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses

Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models

Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection

Methods for the estimation of direct and indirect vaccination effects by combining data from individual‐ and cluster‐randomized trials

Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses

Generalized ROC Methods for Immunogenicity Data Analysis of Vaccine Phase I Studies in a Seropositive Population

Distinguishing Immunologic and Behavioral Effects of Vaccination

HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence

Estimation and Hypothesis Testing of Strain-Specific Vaccine Efficacy with Missing Strain Types, with Applications to a COVID-19 Vaccine Trial

Moving candidate vaccines into development from research: lessons from HIV

Evaluating enrollment and representation in COVID-19 and HIV vaccine clinical trials

Distinguishing immunological and behavioral effects of vaccination